TrialsgrambetaRCTs are beautiful

HOPE

2000

Heart Outcomes Prevention Evaluation

In 9,297 high-risk patients with vascular disease or diabetes and preserved LV function, ramipril reduced MI, stroke, or cardiovascular death compared with placebo.

Result

Efficacy: MI, stroke, or death from cardiovascular causesRR 0.78 (95% CI 0.70-0.86) · P < 0.001

Below 1 favours ramipril, above 1 favours placebo.

Event rates
Absolute difference
3.8 points
NNT
27

Absolute difference and NNT are derived from the event rates.

Also reported: With reductions in CV death (RR 0.74), MI (RR 0.80), stroke (RR 0.68), and all-cause death (RR 0.84).

Original publication
Subtopic
ACE inhibitor
Design
Multicentre double-blind placebo-controlled RCT, 2×2 factorial
Relevance
Important: one of several pillars.
Source
Yusuf S, et al. N Engl J Med. 2000;342(3):145-53.doi 10.1056/NEJM200001203420301

Discussion & critique

The modest BP reduction (~3/2 mmHg) arguably too small to explain the benefit, fuelling mechanism debate; companion vitamin E arm neutral. Established ACE inhibitors for vascular protection in high-risk patients without HF or low EF.

Discussed in podcasts